Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor?

Background: For cannabis-dependent subjects, the relationship between cannabis withdrawal syndrome (CWS) severity and the urine cannabinoid concentrations are unclear; we investigated this using a commercial point-of-care (POC) enzyme immunoassay detecting 11-nor-9-carboxy-Delta-9-tetrahydrocannabin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Psychiatry
Autors principals: Claus, Benedikt Bernd, Specka, Michael, McAnally, Heath, Scherbaum, Norbert, Schifano, Fabrizio, Bonnet, Udo
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Psychiatry
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7744589/
https://ncbi.nlm.nih.gov/pubmed/33343424
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fpsyt.2020.598150
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars